Project Grant R43HL167483
Award Date 7/1/23
Completion Date 6/30/24
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $349,734 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Actiox LLC, a biomedical technology company in Thousand Oaks, California. The project aims to develop a wearable microneedle-based biosensor for continuous, real-time cardiac troponin I monitoring. The goal is to demonstrate the feasibility of this transformative biosensor technology to enable earlier detection of ischemic events and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $388,036 to Laborecom Therapeutics Inc. to develop a novel therapeutic peptide to reduce myocardial reperfusion injury. The goal is to optimize the peptide's stability, permeability, and activity, and then evaluate its ability to improve heart function and limit infarct size in a mouse model of myocardial infarction. Successful completion of this Phase I SBIR...
- This $743,651 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to validate the use of plasma cell-free RNA (cfRNA) as a biomarker for the diagnosis of tuberculosis (TB) and monitoring of treatment. The grant will support the validation of cfRNA signatures in a large patient cohort of 1,378 adults across five countries, and the comparison of cfRNA diagnostic accuracy against...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $694,252.00 to Cedars-Sinai Medical Center in California to investigate the mechanisms of cardioprotective Y RNA signaling in macrophages. The goal is to better understand how a small non-coding RNA called YREX3 can enhance the ability of macrophages to clear dead cells and promote cardiac tissue healing after a myocardial...
- This $312,371 Project Grant award from the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to Biochip Labs Inc., a small business based in Cleveland, Ohio, aims to support the manufacturing and analytical validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for commercial viability. The MIRCA is an in vitro diagnostic technology that measures cellular obstruction in microcapillary networks due to abnormal red blood cell (RBC) deformability...
- The National Heart Lung and Blood Institute awarded a $306,101 Project Grant to Teucer Biotech, Inc. under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) on April 20, 2025. The project aims to develop a novel RT-PCR-based urinary biomarker assay that can predict the development of cardiovascular outcomes earlier and with greater accuracy than current methods such as microalbuminuria. The proposed assay would measure levels of podocyte-specific mRNA in urine samples as...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to evaluate perioperative biomarker-based precision care with targeted long-term use of medications to improve cardiovascular outcomes in patients who experience myocardial injury after non-cardiac surgery (MINS). The $392,037 award to New York University will fund objectives to: 1) conduct site surveys to assess the number of potential MINS...